Penumbra, Inc.
PEN
Pozycja w akcjach
#1697
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
Cena akcji
$320.95
Ostatnia synchronizacja: 2026-10-16
Kapitalizacja rynkowa
$12.64B
Zmiana (1 dzień)
-0.15%
Zmiana (1 rok)
28.90%
Kraj
US
Handel Penumbra, Inc. (PEN)
Kategoria
Healthcare
Marża operacyjna dla Penumbra, Inc. (PEN)
Marża operacyjna na dzień October 2026 TTM: 12.45%
Według najnowszych raportów finansowych i ceny akcji Penumbra, Inc., bieżąca marża operacyjna (TTM) wynosi 12.45%. Na koniec 2023 wynosiła 6.95%.
Historia marży operacyjnej dla Penumbra, Inc. od 2012 do 2026
Marża operacyjna na koniec każdego roku
| Rok | Marża operacyjna | Zmień |
|---|---|---|
| 2026 (TTM) | 12.45% | 1,496.15% |
| 2024 | 0.78% | -88.78% |
| 2023 | 6.95% | 865.28% |
| 2022 | 0.72% | -172.00% |
| 2021 | -1.00% | -85.61% |
| 2020 | -6.95% | -180.07% |
| 2019 | 8.68% | -4,668.42% |
| 2018 | -0.19% | -154.29% |
| 2017 | 0.35% | -168.63% |
| 2016 | -0.51% | -122.67% |
| 2015 | 2.25% | -6.25% |
| 2014 | 2.40% | -288.98% |
| 2013 | -1.27% | -127.08% |
| 2012 | 4.69% | 0.00% |
Marża operacyjna dla podobnych firm lub konkurentów
| Firma | Marża operacyjna | Różnica w marży operacyjnej | Kraj |
|---|---|---|---|
| 17.03% | -98.63% |
US
|
|
| 17.86% | -98.57% |
IE
|
|
| 22.03% | -98.23% |
US
|
|
| 21.46% | -98.28% |
US
|
|
| 0.00% | - |
DE
|
Czym jest marża operacyjna firmy?
Marża operacyjna to kluczowy wskaźnik do oceny rentowności firmy. Wyższe marże operacyjne są zazwyczaj korzystniejsze, ponieważ pokazują, że firma może sprzedawać swoje produkty lub usługi znacznie drożej niż koszty ich produkcji. Oblicza się ją, dzieląc zysk firmy przez jej przychody.